APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

A model for p53-induced apoptosis

Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Impact of mutant p53 functional properties on <i>TP53</i> mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · see citing works

The antioxidant function of the p53 tumor suppressor

Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,110 · see citing works

Cytoplasmic functions of the tumour suppressor p53

Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

Death Signal-induced Localization of p53 Protein to Mitochondria

Marchenko, N. D., Zaika, A. I., & Moll, U. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.16202 · Cited by 902 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802 · see citing works

Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions

Arnér, E. S. J. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.014 · Cited by 675 · see citing works

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works

Reactive oxygen species are downstream mediators of p53-dependent apoptosis.

Johnson, T. M., Yu, Z., Ferrans, V. J., Lowenstein, R. A., & Finkel, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11848 · Cited by 596 · see citing works

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · see citing works

Current Protocols in Toxicology

(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471140856 · Cited by 522 · see citing works

Thioredoxin Reductase Is Irreversibly Modified by Curcumin

Fang, J., Lu, J., & Holmgren, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414645200 · Cited by 521 · see citing works

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 389 · see citing works

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm

Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 366 · see citing works

The thioredoxin-thioredoxin reductase system: over-expression in human cancer.

Lincoln, D. T., Emadi, E. M. A., Tonissen, K. F., & Clarke, F. M. (2003) · PubMed · Cited by 337 · see citing works

Inhibition of Mammalian Thioredoxin Reductase by Some Flavonoids: Implications for Myricetin and Quercetin Anticancer Activity

Lu, J., Papp, L. V., Fang, J., Rodriguez-Nieto, S., Zhivotovsky, B., & Holmgren, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3310 · Cited by 326 · see citing works

Selenoproteins—What unique properties can arise with selenocysteine in place of cysteine?

Arnér, E. S. J. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.032 · Cited by 325 · see citing works

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 320 · see citing works

PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis

Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · see citing works

Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs

Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247 · see citing works

WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization

Tomita, Y. A., Marchenko, N. D., Erster, S. H., Nemajerová, A., Dehner, A., Klein, C., Pan, H., Kessler, H., Pančoška, P., & Moll, U. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507611200 · Cited by 246 · see citing works

The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy

Biaglow, J. E., & Miller, R. A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.1.1434 · Cited by 245 · see citing works

Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy

Tonissen, K. F., & Trapani, G. D. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700492 · Cited by 230 · see citing works

Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds

Witte, A.-B., Anestål, K., Jerremalm, E., Ehrsson, H., & Arnér, E. S. J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.04.025 · Cited by 225 · see citing works

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database

Bykov, V. J. N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2011 · Cited by 172 · see citing works

Rapid Induction of Cell Death by Selenium-compromised Thioredoxin Reductase 1 but Not by the Fully Active Enzyme Containing Selenocysteine

Anestål, K., & Arnér, E. S. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210733200 · Cited by 172 · see citing works

Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells

Anestål, K., Prast‐Nielsen, S., Čėnas, N., & Arnér, E. S. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001846 · Cited by 171 · see citing works

Electrophilic Prostaglandins and Lipid Aldehydes Repress Redox-sensitive Transcription Factors p53 and Hypoxia-inducible Factor by Impairing the Selenoprotein Thioredoxin Reductase

Moos, P. J., Edes, K., Cassidy, P., Massuda, E., & Fitzpatrick, F. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211134200 · Cited by 163 · see citing works

p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer

Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 162 · see citing works

Loss of Thioredoxin Reductase 1 Renders Tumors Highly Susceptible to Pharmacologic Glutathione Deprivation

Mandal, P. K., Schneider, M., Kölle, P., Kuhlencordt, P. J., Förster, H., Beck, H., Bornkamm, G. W., & Conrad, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1509 · Cited by 145 · see citing works

High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy

Eriksson, S. E., Prast‐Nielsen, S., Flaberg, E., Székely, L., & Arnér, E. S. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.016 · Cited by 128 · see citing works

Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II)

Sasada, T., Nakamura, H., Ueda, S., Sato, N., Kitaoka, Y., Gon, Y., Takabayashi, A., Spyrou, G., Holmgren, A., & Yodoi, J. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00101-x · Cited by 124 · see citing works

Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.

Ramqvist, T., Magnússon, K. P., Wang, Y., Székely, L., Klein, G., & Wiman, K. G. (1993) · PubMed · Cited by 120 · see citing works

Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome

Bondareva, A. A., Capecchi, M. R., Iverson, S. V., Li, Y., Lopez, N. I., Lucas, O., Merrill, G. F., Prigge, J. R., Siders, A. M., Wakamiya, M., et al. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.026 · Cited by 117 · see citing works

Mutant p53 targeting by the low molecular weight compound STIMA‐1

Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P. L., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 116 · see citing works

Cytoprotective Nrf2 Pathway Is Induced In Chronically Txnrd 1-Deficient Hepatocytes

Suvorova, E. S., Lucas, O., Weisend, C. M., Rollins, M. F., Merrill, G. F., Capecchi, M. R., & Schmidt, E. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006158 · Cited by 111 · see citing works

p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA

Hedström, E., Eriksson, S. E., Zawacka‐Pankau, J., Arnér, E. S. J., & Selivanova, G. (2009) · Cell Cycle · doi:10.4161/cc.8.21.9977 · Cited by 89 · see citing works

Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1

Prigge, J. R., Eriksson, S. E., Iverson, S. V., Meade, T. A., Capecchi, M. R., Arnér, E. S. J., & Schmidt, E. E. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.11.025 · Cited by 77 · see citing works

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.

(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68 · see citing works

Thioredoxin Reductase Inhibition Elicits Nrf2-Mediated Responses in Clara Cells: Implications for Oxidant-Induced Lung Injury

Locy, M. L., Rogers, L. K., Prigge, J. R., Schmidt, E. E., Arnér, E. S. J., & Tipple, T. E. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4377 · Cited by 60 · see citing works

PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73

Rökaeus, N., Shen, J., Eckhardt, I., Bykov, V. J. N., Wiman, K. G., & Wilhelm, M. (2010) · Oncogene · doi:10.1038/onc.2010.382 · Cited by 60 · see citing works

Mutant p53 rescue and modulation of p53 redox state

Bykov, V. J. N., Lambert, J. M. R., Hainaut, P. L., & Wiman, K. G. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9382 · Cited by 46 · see citing works

APR-246/PRIMA-1 MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations

Shen, J., van den Bogaard, E. H. J., Kouwenhoven, E. N., Bykov, V. J. N., Rinne, T., Zhang, Q., Tjabringa, G. S., Gilissen, C., van Heeringen, S. J., Schalkwijk, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201993110 · Cited by 44 · see citing works

Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase

Xu, J., & Arnér, E. S. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.028 · Cited by 40 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Targeting mutant p53 for efficient cancer therapy

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · see citing works

Mutant p53 as a guardian of the cancer cell

Mantovani, F., Collavin, L., & Sal, G. D. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 779 · see citing works

Modulating ROS to overcome multidrug resistance in cancer

Cui, Q., Wang, J., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D., & Chen, Z. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 664 · see citing works

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 658 · see citing works

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 557 · see citing works

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i> -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465 · see citing works

Mutant p53 as a target for cancer treatment

Duffy, M. J., Synnott, N. C., & Crown, J. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 361 · see citing works

Targeting p53 for the treatment of cancer

Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 351 · see citing works

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321 · see citing works

TP53: an oncogene in disguise

Soussi, T., & Wiman, K. G. (2015) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305 · see citing works

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 292 · see citing works

Recent advances in targeted therapies in acute myeloid leukemia

Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 288 · see citing works

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261 · see citing works

Mutant p53 in cancer therapy—the barrier or the path

Zhou, X. Y., Hao, Q., & Lu, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 244 · see citing works

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

Duffy, M. J., Synnott, N. C., & Crown, J. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 234 · see citing works

Translating p53-based therapies for cancer into the clinic

Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 198 · see citing works

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death &amp; Disease · doi:10.1038/cddis.2015.143 · Cited by 183 · see citing works

Mutant p53 reactivation by small molecules makes its way to the clinic

Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 180 · see citing works

Thioredoxin Reductase Inhibition for Cancer Therapy

Gencheva, R., & Arnér, E. S. J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-102509 · Cited by 178 · see citing works

Towards the overcoming of anticancer drug resistance mediated by p53 mutations

Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 176 · see citing works

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166 · see citing works

Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update

Zhang, J., Zhang, B., Li, X., Han, X., Liu, R., & Fang, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21507 · Cited by 169 · see citing works

TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works

Exploring the multiple roles of guardian of the genome: P53

Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 161 · see citing works

p53 and metabolism: from mechanism to therapeutics

Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 152 · see citing works

Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for <i>TP53</i>-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes

Mishra, A., Tamari, R., DeZern, A. E., Byrne, M. T., Gooptu, M., Chen, Y.-B., Deeg, H. J., Sallman, D., Gallacher, P., Wennborg, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00181 · Cited by 146 · see citing works

Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia

Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132 · see citing works

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy

Bykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137 · see citing works

Understanding cell cycle and cell death regulation provides novel weapons against human diseases

Wiman, K. G., & Zhivotovsky, B. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12609 · Cited by 127 · see citing works

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126 · see citing works

p53 as a hub in cellular redox regulation and therapeutic target in cancer

Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · see citing works

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

Bauer, M. R., Joerger, A. C., & Fersht, A. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610421113 · Cited by 117 · see citing works

Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells

Lisek, K., Campaner, E., Ciani, Y., Walerych, D., & Sal, G. D. (2018) · Oncotarget · doi:10.18632/oncotarget.24974 · Cited by 118 · see citing works

The Function of the Mutant p53-R175H in Cancer

Chiang, Y.-T., Chien, Y., Lin, Y., Wu, H.-H., Lee, D., & Yu, Y. (2021) · Cancers · doi:10.3390/cancers13164088 · Cited by 119 · see citing works

Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?

Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., & Duffy, M. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30425 · Cited by 112 · see citing works

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer

Boullosa, L. F., Loenhout, J. V., Flieswasser, T., Waele, J. D., Hermans, C., Lambrechts, H. A. J., Cuypers, B., Laukens, K., Bartholomeus, E., Siozopoulou, V., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101949 · Cited by 111 · see citing works

Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness

Gamberi, T., Chiappetta, G., Fiaschi, T., Modesti, A., Sorbi, F., & Magherini, F. (2021) · Medicinal Research Reviews · doi:10.1002/med.21872 · Cited by 110 · see citing works

Inhibition of thioredoxin reductase by alantolactone prompts oxidative stress-mediated apoptosis of HeLa cells

Zhang, J., Li, Y., Duan, D., Yao, J., Gao, K., & Fang, J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.004 · Cited by 105 · see citing works

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma

Herrero, A. B., Rojas, E. A., Misiewicz-Krzemińska, I., Krzemiński, P., & Gutierrez, N. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122003 · Cited by 99 · see citing works

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma

Liu, D. S. H., Read, M. D., Cullinane, C. M., Azar, W. J., Fennell, C. M., Montgomery, K. G., Haupt, S., Haupt, Y., Wiman, K. G., Duong, C. P., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309770 · Cited by 95 · see citing works

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

Garcia‐Manero, G., Goldberg, A. D., Winer, E. S., Altman, J. K., Fathi, A. T., Odenike, O. M., Roboz, G. J., Sweet, K. L., Miller, C., Wennborg, A., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00403-3 · Cited by 89 · see citing works

p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells

Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., da Costa, D. C. F., & Silva, J. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004671 · Cited by 89 · see citing works

Drugging “undruggable” genes for cancer treatment: Are we making progress?

Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 85 · see citing works

Targeting the Selenoprotein Thioredoxin Reductase 1 for Anticancer Therapy

Arnér, E. S. J. (2017) · Advances in cancer research · doi:10.1016/bs.acr.2017.07.005 · Cited by 85 · see citing works

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 84 · see citing works

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma

Jovanović, K., Escure, G., Demonchy, J., Willaume, A., de Wyngaert, Z. V., Farhat, M.-M., Chauvet, P., Facon, T. T. F., Quesnel, B., & Manier, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00665 · Cited by 82 · see citing works

Reviving the guardian of the genome: Small molecule activators of p53

Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 80 · see citing works

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

Synnott, N. C., O’Connell, D. J., Crown, J. P., & Duffy, M. J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05435-1 · Cited by 82 · see citing works

Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)

Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78 · see citing works

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246

Haffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73 · see citing works

Therapeutic Inducers of Apoptosis in Ovarian Cancer

Binju, M., Amaya-Padilla, M. A., Wan, G., Gunosewoyo, H., Rahmanto, Y. S., & Yu, Y. (2019) · Cancers · doi:10.3390/cancers11111786 · Cited by 74 · see citing works

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer

Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65 · see citing works

Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1

Hang, W., Yin, Z.-X., Liu, G., Zeng, Q., Shen, X., Sun, Q., Li, D., Jian, Y., Zhang, Y.-H., Wang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0110-2 · Cited by 63 · see citing works

APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

Deben, C., Lardon, F., Wouters, A., de Beeck, K. O., den Bossche, J. V., Jacobs, J., Steen, N. V. D., Peeters, M., Rolfo, C. D., Deschoolmeester, V., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.017 · Cited by 60 · see citing works

Details in the catalytic mechanism of mammalian thioredoxin reductase 1 revealed using point mutations and juglone-coupled enzyme activities

Xu, J., Cheng, Q., & Arnér, E. S. J. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.02.013 · Cited by 56 · see citing works

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia

Demir, S., Boldrin, E., Sun, Q., Hampp, S., Tausch, E., Eckert, C., Ebinger, M., Handgretinger, R., Kronnie, G. T., Wiesmüller, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.199364 · Cited by 55 · see citing works

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

Menichini, P., Monti, P., Speciale, A., Cutrona, G., Matis, S., Fais, F., Taìana, E., Neri, A., Bomben, R., Gentile, M., et al. (2021) · Cells · doi:10.3390/cells10010098 · Cited by 52 · see citing works

Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells

Ali, D., Mohammad, D. K., Mujahed, H., Jonson‐Videsäter, K., Nore, B., Paul, C., & Lehmann, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14036 · Cited by 49 · see citing works

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than <i>TP53</i> Mutation Status

Fujihara, K. M., Corrales Benitez, M., Cabalag, C. S., Zhang, B. Z., Ko, H. S., Liu, D. S., Simpson, K. J., Haupt, Y., Lipton, L., Haupt, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0067 · Cited by 48 · see citing works

Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers

Rotblat, B., Grünewald, T. G. P., Leprivier, G., Melino, G., & Knight, R. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1658 · Cited by 48 · see citing works

Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

Duffy, M. J., Tang, M., Rajaram, S., O’Grady, S., & Crown, J. P. (2022) · Cancers · doi:10.3390/cancers14184499 · Cited by 48 · see citing works

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

Park, H., Shapiro, G. I., Gao, X., Mahipal, A., Starr, J. S., Furqan, M., Singh, P. P., Ahrorov, A., Gandhi, L., Ghosh, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100573 · Cited by 47 · see citing works

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells

Wang, Z., Hu, H., Heitink, L. S., Rogers, K. L., You, Y., Tan, T., Suen, C. S. N. L. W., Garnham, A. L., Chen, H., Lieschke, E., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01122-3 · Cited by 49 · see citing works

p53 and Zinc: A Malleable Relationship

Ha, J., Prela, O., Carpizo, D. R., & Loh, S. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.895887 · Cited by 48 · see citing works

Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling

Zhang, Y., Sun, S., Xu, W., Yang, R., Yang, Y., Guo, J., Ma, K., & Xu, J. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.12.314 · Cited by 45 · see citing works

Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases

Gencheva, R., Cheng, Q., & Arnér, E. S. J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.020 · Cited by 46 · see citing works

Small-molecule correctors and stabilizers to target p53

Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44 · see citing works

Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities

Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 44 · see citing works

Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status

Patyka, M., Sharifi, Z., Petrecca, K., Mansure, J., Jean-Claude, B., & Sabri, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11197 · Cited by 42 · see citing works

The crisscross between p53 and metabolism in cancer

Mao, Y., & Jiang, P. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023109 · Cited by 43 · see citing works

The TP53 tumor suppressor gene: From molecular biology to clinical investigations

Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 45 · see citing works

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death

Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41 · see citing works

New Approaches to Myelodysplastic Syndrome Treatment

Bazinet, A., & Bravo, G. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00965-1 · Cited by 40 · see citing works

PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells

YOSHIKAWA, N., KAJIYAMA, H., NAKAMURA, K., UTSUMI, F., NIIMI, K., MITSUI, H., SEKIYA, R., SUZUKI, S., SHIBATA, K., CALLEN, D., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4653 · Cited by 40 · see citing works

Molecular determinants as therapeutic targets in cancer chemotherapy: An update

Haider, T., Tiwari, R., Vyas, S. P., & Soni, V. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.011 · Cited by 38 · see citing works

Aging tumour cells to cure cancer: “pro-senescence” therapy for cancer

Calcinotto, A., & Alimonti, A. (2017) · Swiss Medical Weekly · doi:10.57187/smw.2017.14367 · Cited by 41 · see citing works

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia

Sallman, D. A. (2020) · Haematologica · doi:10.3324/haematol.2020.249060 · Cited by 37 · see citing works

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

Synnott, N. C., Madden, S. F., Bykov, V. J. N., Crown, J., Wiman, K. G., & Duffy, M. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.009 · Cited by 35 · see citing works

An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53

Huang, Y., Jiao, Z., Fu, Y., Hou, Y., Sun, J., Hu, F., Yu, S., Gong, K., Liu, Y., & Zhao, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116121 · Cited by 33 · see citing works

Battle Against Cancer: An Everlasting Saga of p53

Hao, Q., & Cho, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151222109 · Cited by 35 · see citing works

APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation

Kobayashi, T., Makino, T., Yamashita, K., Saito, T., Tanaka, K., Takahashi, T., Kurokawa, Y., Yamasaki, M., Nakajima, K., Morii, E., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01561-0 · Cited by 33 · see citing works

Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells

Sachweh, M. C. C., Stafford, W. C., Drummond, C. J., McCarthy, A. R., Higgins, M., Campbell, J., Brodin, B. A., Arnér, E. S. J., & Laı́n, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4108 · Cited by 33 · see citing works

PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53

Grellety, T., Laroche‐Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., & Italiano, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1667-1 · Cited by 32 · see citing works

Oxidation of structural cysteine residues in thioredoxin 1 by aromatic arsenicals enhances cancer cell cytotoxicity caused by the inhibition of thioredoxin reductase 1

Zhang, X., Lu, J., Ren, X., Du, Y., Zheng, Y., Ioannou, P. V., & Holmgren, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.010 · Cited by 32 · see citing works

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells

Tessoulin, B., Descamps, G., Dousset, C., Amiot, M., & Pellat-Deceunynck, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00128 · Cited by 31 · see citing works

Novel and emerging targeted-based cancer therapy agents and methods

Hojjat‐Farsangi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3184-x · Cited by 31 · see citing works

Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53

Loh, S. N. (2020) · Biomolecules · doi:10.3390/biom10020303 · Cited by 30 · see citing works

Effects of Mammalian Thioredoxin Reductase Inhibitors

Arnér, E. S. J. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_393 · Cited by 30 · see citing works

Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells

Jiang, L., Malik, N., Acedo, P., & Zawacka‐Pankau, J. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0157-7 · Cited by 29 · see citing works

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies

Magri, J., Gasparetto, A., Conti, L., Calautti, E., Cossu, C., Ruiu, R., Barutello, G., & Cavallo, F. (2021) · Cells · doi:10.3390/cells10010108 · Cited by 29 · see citing works

Discovery of compounds that reactivate p53 mutants in vitro and in vivo

Durairaj, G., Demir, Ö., Lim, B., Baronio, R., Tifrea, D. F., Hall, L., DeForest, J. C., Lauinger, L., Fallatah, M. M. J., Yu, C., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.07.003 · Cited by 29 · see citing works

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation

Teoh, P. J., Bi, C., Sintosebastian, C., Tay, L. S., Fonseca, R., & Chng, W. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11241 · Cited by 28 · see citing works

Current insights into the regulation of programmed cell death by TP53 mutation in cancer

Su, Y., Sai, Y., Zhou, L., Liu, Z., Du, P., Wu, J., & Zhang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023427 · Cited by 28 · see citing works

The Development of p53-Targeted Therapies for Human Cancers

Lu, Y., Wu, M. Y., Xu, Y., & Yu, L. (2023) · Cancers · doi:10.3390/cancers15143560 · Cited by 30 · see citing works

Salvation of the fallen angel: Reactivating mutant p53

Yang, L., Wang, Z., Chen, Y., Petersen, R. B., Zheng, L., & Huang, K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14572 · Cited by 26 · see citing works

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers

Boullosa, L. F., Loenhout, J. V., Flieswasser, T., Hermans, C., Merlin, C., Lau, H. W., Marcq, E., Verschuuren, M., Vos, W. H. D., Lardon, F., et al. (2023) · Antioxidants · doi:10.3390/antiox12030667 · Cited by 27 · see citing works

Emerging role of glutathione peroxidase 4 in myeloid cell lineage development and acute myeloid leukemia

Auberger, P., Favreau, C., Savy, C., Jacquel, A., & Robert, G. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00613-6 · Cited by 26 · see citing works

Multifunctional Compounds for Activation of the p53‐Y220C Mutant in Cancer

Miller, J. J., Orvain, C., Jozi, S., Clarke, R. M., Smith, J. R., Blanchet, A., Gaiddon, C., Warren, J. J., & Storr, T. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201802677 · Cited by 26 · see citing works

Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells

Sun, S., Zhang, Y., Xu, W., Yang, R., Yang, Y., Guo, J., Ma, Q., Ma, K., Zhang, J., & Xu, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112546 · Cited by 26 · see citing works

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246

Haffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73 · see citing works

Mammalian thioredoxin reductase 1 in antioxidant defense, regulation of adipocyte differentiation and as an anticancer drug target

Peng, X. (2015) · Figshare

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy

Bykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137 · see citing works

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death

Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41 · see citing works

The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death

Xu, J., Eriksson, S. E., Cebula, M., Sandalova, T., Hedström, E., Pader, I., Cheng, Q., Myers, C. R., Antholine, W. E., Nagy, P., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2014.574 · Cited by 49 · see citing works